Daniel Wagner

Director, Investments
Connecticut Innovations

Dan Wagner

Dan Wagner

Dan is responsible for evaluating investment opportunities, structuring new investments and monitoring portfolio companies. Dan serves on the boards of CMD Bioscience, FMP Products, Innovatient Solutions, SamiHealth/MyCare, New Haven Pharmaceuticals, P2 Science, RemoteReality Corp. and Synbody Biotechnology. He serves as a board observer for Arvinas, EpiEP and Soft Tissue Regeneration. Dan has also been involved with CI’s investments in Affinimark Technologies, Affomix, Axerion Therapeutics, AxioMx, Cara Therapeutics, CiDRA Corp., CyVek, LiQuifix, Metagenomix, Rib-X Pharmaceuticals, SPOC and ShopText.

Dan bolsters CI experience and expertise in biotech, having worked 10 years in the industry. He was previously employed by successful former CI portfolio company, CuraGen Corporation. While at CuraGen, Dan held a variety of scientific and operational management positions. His extensive experience in research and development, technology assessment, and implementation of next generation scientific technologies enabled Dan to help transform CuraGen from a genomic and proteomic platform company into a biopharmaceutical firm dedicated to advancing its protein, antibody and small molecule therapeutics. Dan represents Connecticut Innovations on the board of the Crossroads Venture Group.

Dan holds a bachelor of science degree in biology from the University of Dayton and earned both master of business administration and master of health sciences degrees from Quinnipiac University.